Podcasts about radiation oncology

Episode 2 of our monthly GU Cast Journal Club and today we focus on two key papers from recent times - the TRANSLATE trial of transperineal vs transrectal biopsy, and Keynote-564 on the role of adjuvant pembrolizomab following nephrectomy.   After great feedback from last month's launch episode, we are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and  Declan Murphy Links to papers and previous podcasts below:1. Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial Lancet Oncology 2025GU Cast on TRANSLATE 2. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma NEJM 2024GU Cast on K-564 OS paper GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

“I think sometimes people don't expect pediatric patients to handle radiation as well as they do. They may have a family member who also had radiation for breast cancer or for prostate cancer and they were an older adult and had really severe side effects. And then they say, ‘Oh, no, I've got to put my little baby through this. I don't really want to do this.' We say kids are very different in how they handle this. They're very resilient, so we can provide good education about that,” Elizabeth Cummings, MSN, CPNP-AC, CPHON®, radiation oncology nurse practitioner at Children's Hospital of Philadelphia in Pennsylvania, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation treatment care for pediatric patients. Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to radiation oncology treatment care for pediatric patients. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 365: Radiation-Associated Secondary Cancers Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles Episode 204: How Radiation Is Used in Palliative Care Episode 50: Difficult Decisions in Childhood Cancer ONS Voice articles: Fertility Preservation Protects Possibilities for Patients With Cancer Have Meaningful Conversations With Pediatric, Adolescent, and Young Adult Patients and Their Families Pediatric Cancer Survivors Require Additional Care and Monitoring Prepare Survivors for the Risk of Secondary Cancers Secondary Cancers in Pediatric Survivors ONS book: Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) ONS courses: Essentials in Survivorship Care for the Advanced Practice Provider ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiation Therapy Survivorship: Healthcare Providers' Perspectives on Education and Care Radiation Therapy: Understanding the Patient Experience Reducing Pediatric Patient Anxiety: Implementing a Nonpharmacologic Intervention to Aid Patients Undergoing Radiation Therapy Other ONS Resources Inclusive Care Learning Library Late Effects of Cancer Treatment Huddle Card Proton Therapy Huddle Card Radiation Huddle Card Radiation Learning Library Oncolink Jr. Pediatric Radiation Oncology Society  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “I think one of the things to think about with kids is sometimes they're not as forthcoming with what's going on, and sometimes it's a little bit harder to understand. Sometimes that's just because developmentally, they're much younger. A 1-year-old can't exactly tell you what's wrong. And so you're really trying to figure it out based on their cues versus a teenager who can tell you, but maybe they're too embarrassed about something in a way that an adult might not be.” TS 7:01 “Child life specialists are incredible. ... They provide age-appropriate education and explanations for patients, so talking to a 3-year-old about cancer is very different from an 8-year-old or even a teenager. They really are able to meet each patient exactly where they are and at the level that they are, and then provide the appropriate amount of information, which is so helpful for a patient since they learn to build trust and cope with their treatment and [they feel like they] have somebody who can relay that information in a clear and concise way.” TS 11:16 “There's certainly growing concern about the potential effects of anesthesia on brain health, especially in a vulnerable population like very young children, which are the ones who need anesthesia. We really try to mitigate this by optimizing our anesthetic agents, so we'll use propofol, which has a really quick onset and offset. And even when the radiation treatment is done, they'll stop the propofol in the radiation room—even though they are still walking back to recovery, just to minimize the amount of time that it's on—and trying to use the lowest dose possible. We also [explore] a lot of nonanesthetic strategies, [like] child life support, trying to introduce video distraction when we can, and having music and audiobooks.” TS 17:47 “[In] pediatrics, the patient, not the parent, is your patient. And that can look really different for a 3-year-old versus a 17-year-old. Somebody who can't officially sign consent, but they certainly have a lot of buy-in about the things that reach their body, versus a 3-year-old, where the parents are really taking ownership of that. I think sometimes it's tricky in the world of pediatrics as we think about the ethics of ‘Who are we training here? Is it the patients? Is it the parents?' And we continue to advocate for our patients.” TS 23:32 “I think that pediatric patients still want to be normal kids. They still want to do their normal activities. ... Our pediatric patients, a lot of times, have healthier tissues. They haven't seen as much wear and tear. They haven't developed the bad habits of some adults. They don't have the same environmental exposures, they're not smoking, they probably have fewer comorbidities. ... They're a different population. ... They're just amazing. They still want to be a kid, they still want to go to school, they still want to be with their friends. It's really encouraging to see that.” TS 36:03 

In this episode of the ACRO Podcast CURiE Conversations edition, Dr. Jenna Kahn speaks with authors Dr. Scott Silva and med student Caitlin Reichard about their published article, "Dosimetry, Toxicity, and Outcomes of Medically Inoperable Endometrial Cancer Treated With Definitive External Beam Radiation Therapy and Brachytherapy." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article here: https://www.cureus.com/articles/366834-dosimetry-toxicity-and-outcomes-of-medically-inoperable-endometrial-cancer-treated-with-definitive-external-beam-radiation-therapy-and-brachytherapy#!/

For W. Neil Duggar, PhD, DABR, everything on his path to leadership in academic medicine started with fully understanding his own “why.” That process of understanding your purpose, who you are, and how that dictates what success will look like, and whether you are making progress, is a central theme within today's broader leadership discussion.  Dr. Duggar currently serves as an Associate Professor and Director of Medical Physics in the Department of Radiation Oncology at the University of Mississippi Medical Center in Jackson.  Learning to lead without formal authority is important in our field because, as Dr. Duggar puts it, “most of us don't have authority or a title most of our careers, if we ever do get one, so learning to lead without authority becomes a very powerful combination of skills.”  Embracing feedback and constructive criticism about yourself is vital to this discussion because, without this journey to self-awareness, it's very easy for leaders to fall into the trap of “your own legend.”  “You can start believing your opinion and feedback are most important, but the reality is that there will always be voices you need to listen to outside of your own,” he said.  We thank Dr. Duggar for reaching out to us via the Faculty Factory inbox and requesting to be a guest on this show! If you have something to share within your corner of the academic medicine world as a guest, please send us a message: https://facultyfactory.org/contact-us/    After you listen to Dr. Duggar's interview, for more fantastic podcast episodes, please check out our show's archives: https://facultyfactory.org/podcast-topics/

Dr. Kathleen Horst, Dr. Rachel Jimenez, and Dr. Yara Abdou discuss the updated guideline from ASTRO, ASCO, and SSO on postmastectomy radiation therapy. They share new and updated recommendations on topics including PMRT after upfront surgery, PMRT after neoadjuvant systemic therapy, dose and fractionation schedules, and delivery techniques. They comment on the importance of a multidisciplinary approach and providing personalized care based on individual patient characteristics. Finally, they review ongoing research that may impact these evidence-based guidelines in the future. Read the full guideline, “Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline” at www.asco.org/breast-cancer-guidelines" TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01747  Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Kathleen Horst, expert panel chair from Stanford University; Dr. Rachel Jimenez, expert panel vice chair from Massachusetts General Hospital; and Dr. Yara Abdou, ASCO representative from the University of North Carolina, authors on "Postmastectomy Radiation Therapy: An American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology Clinical Practice Guideline." Thank you for being here today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Kathleen Horst: Thank you for having us. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Horst, Dr. Jimenez, and Dr. Abdou who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Then to dive into the content that we are here today to talk about, Dr. Horst, could you start us off by describing what prompted the update for this joint guideline between ASTRO, ASCO, and SSO, and what is the scope of this 2025 guideline on postmastectomy radiation therapy? Dr. Kathleen Horst: Thank you. This joint guideline was last updated in 2016. Over the past decade, the treatment of breast cancer has evolved substantially. Newer systemic therapy regimens have increasingly personalized treatment based on tumor biology, and local therapy management has explored both the de-escalation of axillary surgery and more abbreviated courses of radiation therapy. Given these advances, it was important to revisit the role of postmastectomy radiotherapy in this modern era of breast cancer therapy. This updated guideline addresses four key questions, including postmastectomy radiation therapy after upfront surgery as well as after neoadjuvant systemic therapy. It also reviews the evolving role of various dose and fractionation schedules and optimal treatment techniques and dose constraints. Brittany Harvey: Excellent. I appreciate that background, Dr. Horst. So then, next, Dr. Jimenez, I would like to review the recommendations of this guideline across those four key questions that Dr. Horst just mentioned. So first, what does the panel recommend for PMRT for patients who received initial treatment with mastectomy? Dr. Rachel Jimenez: The panel provided pretty strong consensus that patients with positive lymph nodes or patients with large tumors involving the skin or the chest wall should receive postmastectomy radiation. However, the panel also recognized that the omission of postmastectomy radiation may be appropriate for select patients who have positive lymph nodes and have an axillary lymph node dissection if they have a low nodal burden and other favorable clinical or pathologic features. For patients without lymph node involvement at the time of surgery and no involvement of the skin or chest wall, postmastectomy radiation was not advised by the panel. Brittany Harvey: Understood. It is helpful to understand those recommendations for that patient population. Following that, Dr. Abdou, what are the key recommendations for PMRT for patients who received neoadjuvant systemic therapy before mastectomy? Dr. Yara Abdou: When we think about PMRT after neoadjuvant treatment, the key point is that the initial stage of presentation still matters a lot. So for example, if a patient comes in with more advanced disease, say a large primary tumor, like a clinical T4, or more extensive nodal disease, like an N2 or N3 disease, those patients should get PMRT, no matter how well they respond to neoadjuvant therapy, because we know it reduces the risk of recurrence and that has been shown pretty consistently. On the other hand, if there are still positive lymph nodes after neoadjuvant treatment, basically residual nodal disease, PMRT is also strongly recommended because the risk of local-regional recurrence is much higher in that setting. The gray area is the group of patients who start with a lower burden of nodal disease, such as N1 disease, but then become node negative at surgery. For those patients, we tend to individualize the decision. So if the patient is young or has triple-negative disease, or if there is a lot of residual disease in the breast even though the nodes are cleared, then radiation is probably helpful. But if everything has melted away with pCR in both the breast and the nodes, then it may be safe to omit PMRT in those patients. For patients with smaller tumors and no nodal involvement to begin with, like a clinical T1-T2 N0, if they are still node negative after neoadjuvant treatment, then PMRT is generally not recommended because their baseline recurrence risk is low. And finally, if the margins are positive and cannot be re-excised, then PMRT is recommended after neoadjuvant therapy. Brittany Harvey: Yes, those distinctions are important for appropriate patient selection. So then, Dr. Horst, we have just reviewed the indications for PMRT, but for those patients who receive PMRT, what are the appropriate treatment volumes and dose fractionation regimens? Dr. Kathleen Horst: The guideline addresses coverage of the chest wall and regional nodes with a specific discussion of the data regarding internal mammary nodal irradiation, which has been an area of controversy over many years. The guideline also reviews the data exploring moderate hypofractionation, or shorter courses of radiation therapy. The task force recommends utilizing moderate hypofractionation for the majority of women requiring postmastectomy radiation, which is likely to have a large impact on clinical practice. This recommendation is based on the evolving data demonstrating that a 3-week course of radiotherapy after mastectomy provides similar oncologic outcomes and minimal toxicity for most patients compared to the standard 5-week treatment course. Brittany Harvey: Thank you for reviewing that set of recommendations as well. So then, Dr. Jimenez, to wrap us up on the key questions here, what delivery techniques are recommended for treating patients who receive PMRT? Dr. Rachel Jimenez: So this portion of the guideline is likely to be most helpful for radiation oncologists because it represents the most technical part of the guideline, but we do believe that it offers some important guidance that has, to this point, been lacking in the postmastectomy radiation setting. So first, the panel recommends that all patients should undergo 3-dimensional radiation planning using CAT scan based imaging, and this includes contouring. So contouring refers to the explicit identification, using a drawing interface on the CAT scan imaging, by the radiation oncologist to identify the areas that are targeted to receive radiation, as well as all of the nearby normal tissues that could receive unintended radiation exposure. And we also provide radiation oncologists in the guideline with suggestions about how much dose each target tissue should receive and what the dose limits should be for normal tissues. Additionally, we make some recommendations regarding the manner in which radiation is delivered. So for example, we advise that when conventional radiation methods are not sufficient for covering the areas of the body that are still at risk for cancer, or where too high of a dose of radiation would be anticipated to a normal part of the body, that providers employ a technique called intensity modulated radiation therapy, or IMRT. And if IMRT is going to be used, we also advise regular 3-dimensional imaging assessments of the patient's body relative to the treatment machine to ensure treatment fidelity. When the treatments are delivered, we further advise using a deep inspiration breath-hold technique, which lowers the exposure to the heart and to the lungs when there is concern for cardiopulmonary radiation exposure, and again, that image guidance be used along with real-time monitoring of the patient's anatomy when those techniques are employed. And then finally, we advise that patients receiving postmastectomy radiation utilize a bolus, or a synthetic substance placed on the patient's skin to enhance radiation dose to the superficial tissue, only when there is involvement of the skin with cancer or other high-risk features of the cancer, but not for every patient who receives postmastectomy radiation. Brittany Harvey: Understood. And then, yes, you just mentioned that section of the guideline is probably most helpful for radiation oncologists, but I think you can all comment on this next question. What should all clinicians, including radiation oncologists, surgical oncologists, medical oncologists, and other oncologic professionals, know as they implement all of these updated recommendations? Dr. Rachel Jimenez: So I think one of the things that is most important when we consider postmastectomy radiation and making recommendations is that this is a multidisciplinary panel and that we would expect and encourage our colleagues, as they interpret the guidelines, to employ a multidisciplinary approach when they are discussing each individual patient with their surgical and medical oncology colleagues, that there is no one size fits all. So these guidelines are intended to provide some general guidance around the most appropriate techniques and approaches and recommendations for the utilization of postmastectomy radiation, but that we recognize that all of these recommendations should be individualized for patients and also represent somewhat of a moving target as additional studies, both in the surgical and radiation oncology realm as well as in the systemic therapy realm, enter our milieu, we have to adjust those recommendations accordingly. Dr. Kathleen Horst: Yeah, I would agree, and I wanted to comment as a radiation oncologist, we recognize that local-regional considerations are intertwined with systemic therapy considerations. So as the data evolve, it is critical to have these ongoing updates in a cross-disciplinary manner to ensure optimal care for our patients. And as Dr. Jimenez mentioned, these multidisciplinary discussions are critical for all of us to continue to learn and understand the evolving recommendations across disciplines but also to individualize them according to individual patients. Dr. Yara Abdou: I could not agree more. I think from a medical oncology perspective, systemic therapy has gotten much better with adjuvant CDK4/6 inhibitors, T-DM1, capecitabine, and immune therapy. So these are all newer adjuvant therapies, so the baseline recurrence risks are lower than what they were in the trials that established PMRT. So the absolute benefit of radiation varies more now, so smaller for favorable biology but still relevant in aggressive subtypes or with residual disease. So it is definitely not a one-size-fits-all. Brittany Harvey: Yes, I think it is important that you have all highlighted that multidisciplinary approach and having individualized, patient-centric care. So then, expanding on that just a little bit, Dr. Abdou, how will these guideline recommendations affect patients with breast cancer? Dr. Yara Abdou: So basically, reiterating what we just talked about, these guidelines really move us towards personalized care. So for patients at higher risk, so those with larger tumors, multiple positive nodes, or residual nodal disease after neoadjuvant therapy, PMRT remains essential, consistently lowering local-regional recurrence and improving survival. But for patients at intermediate or lower risk, the recommendations support a more selective approach. So instead of a blanket rule, we now integrate tumor biology, response to systemic therapy, and individual patient factors to decide when PMRT adds meaningful benefit. So the impact for patients is really important because those at high risk continue to get the survival advantage of radiation while others can be spared the unnecessary treatment and side effects. So in short, we are aligning PMRT with modern systemic therapy and biology, making sure each patient receives the right treatment for their situation. Brittany Harvey: Absolutely. Individualizing treatment to every patient will make sure that everyone can achieve the best outcomes as possible. So then, Dr. Jimenez, to wrap us up, I believe Dr. Horst mentioned earlier that data continues to evolve in this field. So in your opinion, what are the outstanding questions regarding the use of PMRT and what are you looking to for the future of research in this space? Dr. Rachel Jimenez: So there are a number of randomized phase III clinical trials that are either in active accrual or that have reported but not yet published that are exploring further de-escalation of postmastectomy radiation and of axillary surgery. And so we do not yet have sufficient data to understand how those two pieces of information integrate with each other. So for example, if you have a patient who has a positive lymph node at the time of diagnosis and forgoes axillary surgery aside from a sentinel lymph node biopsy, we do not yet know that we can also safely forgo radiation entirely in that setting. So we expect that future studies are going to address these questions and understand when it is appropriate to simultaneously de-escalate surgery and radiation. Additionally, there is a number of trials that are looking at ways in which radiation could be omitted or shortened. So there is the RT CHARM trial, which has reported but not yet published, looking at a shorter course of radiation. And so we do make recommendations around that shorter course of radiation in this guideline, but we anticipate that the additional data from the RT CHARM study will provide further evidence in support of that. Additionally, there is a study called the TAILOR RT trial, which looks at forgoing postmastectomy radiation in patients who, to Dr. Abdou's point, have a favorable tumor biology and a low 21-gene recurrence score. And so we are going to anticipate the results from that study to help guide who can selectively forgo postmastectomy radiation when they fall into that favorable risk category. So there are a number of questions that I think will help flesh out this guideline. And as they publish, we will likely publish a focused update on that information to help provide context for our colleagues in the field and clarify some of these recommendations to suit the latest data. Brittany Harvey: Absolutely. We will look forward to those de-escalation trials and ongoing research in the field to build on the evidence and look for future updates to this guideline. So I want to thank you for your work to update these guidelines, and thank you for your time today, Dr. Horst, Dr. Jimenez, and Dr. Abdou. Dr. Rachel Jimenez: Thank you. Dr. Yara Abdou: Thank you. Dr. Kathleen Horst: Thank you. Brittany Harvey: And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Check out this week's QuadCast as we highlight the limited role of axillary dissection in breast cancer, the benefits of SBRT in oligometastatic renal cell carcinoma, more data on ultra central lung cancer radiation, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

At Sarasota Memorial, the multi-disciplinary cancer care team provides prostate screening and diagnostic biopsy services, along with comprehensive care. Kunal Saigal, MD, Medical Director of Radiation Oncology at the Brian D. Jellison Cancer Institute, discusses the latest advancements in prostate cancer treatment, including the use of Pluvicto.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

What if prostate cancer treatment weren't months of daily radiation—but five ultra-precise sessions guided in real time by MRI? Today, Dr. Michael J. Zelefsky (Professor of Radiation Oncology, NYU Grossman School of Medicine) explains how MRI-LINAC and adaptive planning are redefining accuracy, reducing side effects, and personalizing care. A pioneer behind IMRT and image-guided radiotherapy, Dr. Zelefsky breaks down SBRT vs. IMRT, protons vs. photons, HDR brachytherapy, when to add hormone therapy, and how genomics + AI are shaping what's next.In this conversation, Dr. Zelefsky charts the evolution from long-course radiation to short-course SBRT with outcomes comparable to 7–9 week regimens—thanks to precision imaging and planning. He clarifies where IMRT ends and SBRT begins, why protons haven't shown superiority over photons in prostate cancer, and where HDR brachytherapy (Ir-192) shines—especially as a boost in higher-risk disease. We dig into dose equivalence (why 5×8 Gy can match ~80–90 Gy long-course), risk-based treatment + ADT duration, and how Decipher/Artera scores can refine decisions. Most exciting: MRI-LINAC with continuous motion monitoring keeps the prostate in a virtual “bullseye,” enabling whole-gland treatment with focal boosts today—and potentially true focal therapy tomorrow as biologic imaging and AI mature.Time-Stamped Highlights00:00 – Welcome 02:00 – Why Dr. Zelefsky's work is so respected; career arc and impact04:00 – What changed: CT/MRI planning → 3D-CRT → IMRT → SBRT12:45 – IMRT vs. SBRT: definitions, session counts, who gets what19:10 – Energy sources overview: photons, protons, brachytherapy20:30 – Protons vs. photons: evidence, indications, cost, access24:00 – HDR brachytherapy (Ir-192) as a temporary “in-and-out” boost28:00 – Dose logic: why 5×8 Gy (~40 Gy) ≈ long-course 80–90 Gy29:30 – Risk groups (low/intermediate/high) and when ADT is crucial33:00 – ADT durations (6–36 months): what trials actually showed37:00 – Genomics (Decipher/Artera): resolving risk discrepancies39:00 – What MRI-LINAC adds: real-time adaptive planning43:00 – Continuous Motion Monitoring (CMM): beam stops if target moves47:00 – Treat whole gland + boost the DIL (FLAME study approach)49:00 – Toward focal therapy with better biologic imaging + AI54:00 – How to choose: values, side-effects, lifestyle, comorbidities01:01:00 – Final guidance: don't be overwhelmed—multiple good option

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 2025 World Conference on Lung Cancer. Dr. Cho is a radiation oncologist at Princess Margaret Cancer Centre and an Associate Professor in the Department of Radiation Oncology at the University of Toronto.

Check out this week's QuadCast where we highlight the pros and cons of dose de-escalated RT for resected HPV+ oropharynx cancer, another trial showing that SBRT for oligometastatic prostate cancer improves outcomes, a model for predicting brain radiation necrosis with SRS, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Guest: Ann Klopp, M.D., Ph.D. The recent NRG0238 trial evaluated whether adding chemotherapy to radiation improves outcomes in patients with localized endometrial cancer recurrences. Hear from Dr. Ann Klopp as she explains the findings and how they could shift practice patterns for patient care. Dr. Klopp is a Professor of Radiation Oncology, the Director of Brachytherapy, and the leader of the gynecologic section in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center in Houston.

Guest: Ann Klopp, M.D., Ph.D. Endometrial cancer treatment is continuing to evolve, with surgery guiding initial decisions and new evidence showing that adding immunotherapy significantly improves outcomes in advanced disease. But key questions remain around tailoring regimens to individual patients. Dr. Ann Klopp highlights the latest advances and challenges in management, particularly in patients with pelvic recurrences. Dr. Klopp is a Professor of Radiation Oncology, the Director of Brachytherapy, and the leader of the gynecologic section at the University of Texas MD Anderson Cancer Center in Houston.

Here it is, the first of our new series called GU Cast Journal Club! A dedicated GU Cast Journal Club has been suggested by many of our listeners and viewers over the years, and we are really pleased to kick off today with the first monthly episode. And we are particularly pleased to introduce our GU Cast Journal Club Editors, Dr Carlso Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER). Declan Murphy is anchoring today's episode while Renu is busy elsewhere. Each month, two papers will be discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU OncologyThe objective is to draw attention to important papers in GU Oncology, and critique these in a robust mannerThe key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series. For this inaugural epsiode, we have selected two very important recent papers:1. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial 2. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant. 

In this episode of the ACRO Podcast CURiE Conversations edition, Dr. Jessica Schuster speaks with author Dr. Leslie Chang about her published article, "Advancing Professionalism Through a Patient Safety and Quality Improvement Workshop in Radiation Oncology." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article here: https://www.cureus.com/articles/372473-advancing-professionalism-through-a-patient-safety-and-quality-improvement-workshop-in-radiation-oncology#!/

In this episode, Mason sits down with Dr. Carol Haddad to explore a topic close to the hearts of so many—how traditional medical treatments and complementary approaches can work together for deeper healing. Instead of choosing one path over the other, Dr. Carol shares how integration creates a more personalized, compassionate, and effective journey toward wellness. You'll hear real-world examples, practical strategies, and encouraging insights that remind us healing isn't just about treating the body—it's about nurturing the whole person: mind, body, and spirit. Whether you're a patient, caregiver, or simply curious about integrative approaches, this conversation offers hope, wisdom, and a refreshing perspective on what's possible when different worlds of medicine come together. By the end of this episode, you'll feel empowered with new ways to think about health, inspired by stories of resilience, and encouraged to see healing as more than a diagnosis—it's a journey.   Key Insights & Timestamps 02:15 The importance of blending science with holistic approaches 05:42 Why patients shouldn't feel forced to choose “either/or” in treatment 09:10 Dr. Carol's story of how she embraced integrative care 14:27 The role of nutrition and lifestyle in healing 18:55 How mindset and emotional health impact physical recovery 23:40 The science behind complementary therapies 28:05 Stories of patients who found strength through integrative care 33:12 How caregivers can support the journey with compassion 38:46 The future of medicine: collaboration over competition 42:19 Practical steps to begin your own integrative path About Dr. Carol Haddad Dr. Carol is a highly trained physician who bridges the gap between conventional oncology and holistic healing. With a background that includes a Medical Science degree from UNSW, a postgraduate degree in Medicine from the University of Sydney, specialty training in Radiation Oncology, and certification in Functional Medicine, she has more than a decade of experience treating patients within hospital and cancer center settings. Her journey led her beyond traditional medicine into the world of integrative oncology, where she combines evidence-based treatments with complementary therapies such as natural medicine, psycho-energetic healing, nutrition, and lifestyle interventions. This unique approach allows her to deliver truly holistic cancer care—addressing not just the disease, but the whole person. Dr. Carol believes that patients deserve a more balanced model of treatment, one that draws from the strengths of both science and spirituality to improve outcomes and quality of life. Today, she consults with patients and healthcare professionals worldwide, offering guidance on functional medicine, integrative cancer strategies, and ways to minimise side effects while maximising recovery. Her mission is to empower individuals to embrace long-term wellbeing, reduce recurrence risk, and experience healing in a more sustainable way. If you're curious about functional medicine, holistic oncology, or integrative cancer support, this episode is for you.   Resources Mentioned: Email: drcarolhaddad@gmail.com Website: www.drcarolhaddad.com

Access the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/What lifestyle choices can reduce your risk before cancer develops? (Video ReRelease)Dr. Katie Deming sat down with Dr. Thomas Seyfried, professor of biology at Boston College and author of Cancer as a Metabolic Disease. Together, they explore how cancer cells depend on sugar and glutamine for fuel, why the mitochondria, not DNA mutations, may be at the heart of the disease, and what this understanding means for prevention and treatment.Key Highlights:Can dietary changes, fasting, and exercise support treatment once cancer is diagnosed? Why should patients and doctors pay attention to the Glucose Ketone Index (GKI) to measure how the body is fueling itself?What can you do today to reduce your risk of chronic illness?Dr. Seyfried explains the Warburg Effect, the role of dysfunctional mitochondria in cancer growth, and why standard treatments may sometimes work against us by feeding cancer's energy needs.Listen, learn the surprising story of how weight loss, not a new drug, led to dramatic tumor reduction in lab studies. Dr. Thomas Seyfried: https://www.bc.edu/bc-web/schools/morrissey/departments/biology/people/faculty-directory/thomas-seyfried.htmlAccess the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Save your spot for the next LIVE fasting call here: https://www.katiedeming.com/the-healing-power-of-fasting/ Work with Dr. Katie: www.katiedeming.comEmail: INFO@KATIEDEMING.COM 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

Check out this week's QuadCast as we highlight the ability to skip a mediastinal nodal dissection with small GGOs, how Pluvicto improves outcomes in mCRPC with higher tumor volume, the lack of general knowledge about the link between HPV and oropharyngeal cancer, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Check out this week's QuadCast as we highlight how intranasal mupirocin decreases radiation dermatitis associate with nasopharynx radiation, the lack of benefit of immunotherapy in MGMT-unmethylated GBM, the role of neoadjuvant chemoradiation in unresectable pancreatic cancer, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

In this episode of 'Conversations in Lung Cancer Research,' A/Prof Mel Moore sits down with A/Prof Fiona Hegi Johnson, a radiation oncologist at the Peter McCallum Cancer Center and senior research fellow at the University of Melbourne. Fiona shares her journey into radiation oncology, highlighting her career progression, the impact of serendipity, and the importance of mentors. They discuss technological advancements in the field, the role of multidisciplinary teams, changes in lung cancer treatments, and clinical challenges. Fiona offers insights into balancing clinical work with research and provides advice for early-career professionals in the field.(00:00) Introduction and Acknowledgements(00:32) Guest Introduction: Associate Professor Fiona Hegi Johnson(01:33) Fiona's Career Journey and Early Challenges(04:08) Choosing Radiation Oncology(06:04) Balancing Clinical and Academic Roles(09:46) Challenges in Radiation Oncology Research(13:45) Technological Advances in Lung Cancer Treatment(17:22) Multidisciplinary Team Dynamics(23:03) Fiona's Role in TROG and Mentorship(28:32) Advice for Early Career Professionals(30:02) Conclusion and Final Thoughts

Check out this week's QuadCast as we highlight long term results from FLAME on DIL SIB in prostate cancer, how the benefits of Pluvicto are growing, the thought provoking question of surgical omission in breast cancer, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Check out this week's QuadCast as we highlight de-escalated therapy for cutaneous SCC based on pembro response, a comparison of fluciclovine vs. PSMA PET scan in biochemically recurrent prostate cancer, an important change to HPV+ oropharyngeal staging, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Dr Akila Viswanathan speaks with Dr Sophia Kamran from Harvard Medical School and Dr Constantinos Zamboglou from the German Oncology Center about the latest edition of Seminars in Radiation Oncology focusing on new treatments for advanced prostate cancer.

When it comes to spinal oncology, no single specialty holds all the answers. In this episode of the BackTable Podcast, host Dr. Alexa Levey, an interventional radiologist from Yale School of Medicine, is joined by Dr. Mark Amsbaugh, a radiation oncologist, and Dr. Ran Lador, an orthopedic spine surgeon, both from the University of Texas McGovern Medical School. The discussion explores complexities and innovations in the multidisciplinary treatment of spinal tumors. --- SYNPOSIS Dr. Ambsbaugh and Dr. Lador highlight their cohesive, patient-centered approach at Memorial Hermann, integrating various specialties including surgery, radiation oncology, and interventional radiology. The episode emphasizes the importance of collaborative techniques, advances in minimally invasive surgeries, the role of stereotactic radiosurgery, and the critical nature of personalized patient care in improving outcomes for patients with spinal tumors. --- TIMESTAMPS 00:00 - Introduction01:20 - Multidisciplinary Approach to Spinal Tumors at Memorial Hermann10:22 - Surgical Techniques and Timing for Radiation Treatments 12:25 - Approach to Collaborative Treatment Planning25:45 - Connection Between Surgical and Radiation Oncology in Patient Care31:08 - The Role of Vertebral Augmentation in Spinal Oncology40:08 - Multimodal Pain Management Strategies47:35 - Thoughts on Future Directions in Spinal Oncology and Conclusion --- RESOURCES Dr. Mark Amsbaugh, MDhttps://med.uth.edu/neurosciences/dr-mark-j-amsbaugh-md/ Dr. Ran Lador, MDhttps://med.uth.edu/ortho/2022/11/02/ran-lador-md/ Dr. Alexa Levey, MDhttps://medicine.yale.edu/profile/alexa-levey/

Check out this week's QuadCast as we highlight the impact of perilesional edema on local failure risk for brain SRS, the benefits of RT in high risk prostate cancer, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

GDP Script/ Top Stories for July 24th Publish Date: July 24th From the BG AD Group Studio Welcome to the Gwinnett Daily Post Podcast. Today is Thursday, July 24th and Happy birthday to Barry Bonds I’m Peyton Spurlock and here are your top stories presented by KIA Mall of Georgia. Northside Hospital Cancer Institute acquires Snellville radiation oncology clinic Gwinnett schools will roll out weapons detection systems in August Gwinnett student places third at Microsoft Office Specialist National Championship Plus, Leah McGrath from Ingles Markets on diabetes All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe! Break 1: 07.14.22 KIA MOG STORY 1: Northside Hospital Cancer Institute acquires Snellville radiation oncology clinic Northside Hospital's Cancer Institute has expanded its network by acquiring five radiation oncology clinics, including one in Snellville, enhancing access to advanced cancer treatments in south Gwinnett. The Snellville clinic, located at 1770 Presidential Circle, joins locations in Decatur, Covington, Conyers, and Blairsville. Northside officials emphasize the convenience and quality of care provided by their multidisciplinary team, offering techniques like external beam radiation and stereotactic radiosurgery. The clinics will retain their existing providers and services, ensuring continuity and compassionate care for patients. STORY 2: Gwinnett schools will roll out weapons detection systems in August Gwinnett County Public Schools will roll out weapons detection systems in all middle and high schools starting later in August, following a $19.3 million investment approved by the school board. These systems aim to enhance safety after last year’s Apalachee High School shooting. The devices, already used in athletic venues, will be installed at multiple entrances for morning intake and at main entrances during school hours. The district is also hiring 15 additional school resource officers for elementary schools, working toward a long-term goal of one officer per school. This initiative is part of a three-pronged safety approach focusing on prevention, protection, and response. STORY 3: Gwinnett student places third at Microsoft Office Specialist National Championship Allena Nguyen, a rising junior at Gwinnett Online Campus, earned third place in the 2025 Certiport Microsoft Office Specialist National Championship, competing in the Microsoft PowerPoint category. She was the only Georgia resident to place, winning a $1,000 cash prize. Nguyen excelled at the Georgia Spring Qualifier with perfect scores and the fastest times, earning her a spot among 187 national contestants. Principal Bo Ford praised her dedication and passion for technology, highlighting her as a role model for student success. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info. We’ll be right back Break 2: DTL MOVIE CLUB And now here is Leah McGrath from Ingles Markets on diabetes STORY 6: Shane Foye of Peachtree Cornes named to UGA's 40 Under 40 Class of 2025 The University of Georgia has announced its 40 Under 40 Class of 2025, honoring young alumni for their achievements in various fields, including medicine, sports, and space exploration. Among the honorees is Shane Foye of Peachtree Corners, president of DW1 and an active UGA supporter. The group will be celebrated at a September awards luncheon on campus. Selected from hundreds of nominations, these alumni embody UGA’s principles of wisdom, justice, and moderation, showcasing the university’s impact on their success and contributions to their communities. STORY 7: Gwinnett County to host Household Hazardous Waste Collection Day Saturday Gwinnett County's Household Hazardous Waste Collection Day returns on July 26 at the Gwinnett County Fairgrounds from 8 a.m. to noon. Co-hosted by Gwinnett Clean & Beautiful and the Department of Water Resources, the event helps residents safely dispose of hazardous items like paints, batteries, and pesticides. Volunteers are needed to assist with traffic and material handling. Residents can bring up to five containers of waste for free, but items like ammunition, biohazard waste, and electronics will not be accepted. The event has grown significantly, with over 1,000 vehicles attending in February. Break 3: We’ll have closing comments after this Break 4: Ingles Markets 7 Signoff – Thanks again for hanging out with us on today’s Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: ingles-markets.com kiamallofga.com #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversationsSee omnystudio.com/listener for privacy information.

On December 5, 2025, we will kick off the IASLC ASCO 2025 North America Conference on Lung Cancer. Guest include Dr. Ramesh Rengan, the Peter Wootton Professor and Chair of Radiation Oncology at the University of Washington and Senior Vice President of the Fred Hutchinson Cancer Center and Dr. Kristen Marrone, Associate Professor of Oncology and Director of the Medical Oncology and Hematology Fellowship Program at Johns Hopkins University.

Check out this week's QuadCast as we highlight a PSMA Theranostic contender, new guidelines (and name) for GBM, current management limitations in NSCLC, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Patricia Mae Santos is an assistant professor in the Department of Radiation Oncology at Emory University School of Medicine. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. P.M.G. Santos, R. Jagsi, and C.I.A. Oronce. Who Will Care for America? Immigration Policy and the Coming Health Workforce Crisis. N Engl J Med 2025;393:105-107.

Figures released today from the Irish Cancer Society show a significant variation in access to cancer treatment across the country which it says is causing avoidable deaths. Full analysis from Professor John Armstrong, President, Irish Society of Radiation Oncology and Radiation Oncologist, St Luke's Hospital.

Check out this episode of the QuadCast where we highlight de-intensification for HPV mediated oropharyngeal squamous cell carcinoma, how the addition of radium 223 to enzalutamide improves outcomes, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

In this episode of the ACRO podcast CURiE edition, CURiE Channel Editor Dr. Jessica Schuster speaks with author Dr. Shearwood McClelland, III about his published article, "Early Implementation of the Navigator-Assisted Hypofractionation (NAVAH) Program in Hispanic-American Breast Cancer Patients." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science.Read the article here: https://www.cureus.com/articles/363179-early-implementation-of-the-navigator-assisted-hypofractionation-navah-program-in-hispanic-american-breast-cancer-patients#!/

If you're anything like me, you might find the process of what happens to patients when they visit a radiation oncologist somewhat mysterious. During my training, I didn't receive much education about radiation oncology, and I'm not entirely sure what some of the terms mean (hypofractionated means fewer sessions, right?). Well, today's podcast aims to clear up all these uncertainties. We've invited Anish Butala, the Chief of the Palliative Radiotherapy Service at Penn Medicine, and Emily Martin, a palliative care doctor and past president of the Society for Palliative Radiation Oncology (SPRO), to explain everything we should know about radiation oncology. Additionally, Evie Kalmar, who suggested today's topic, will join us as one of our guest hosts. Tune in and we will walk you through the patient's journey from the initial planning visit to the final treatment, discuss common indications like bone and brain metastases, hear about when to consider steroid therapy, and highlight radiation therapy emergencies.

Radiation Therapy can seem daunting, but it doesn't have to be. Tune in to TALRadio English on Spotify & Apple Podcasts for a compelling interview with Dr. K.C. Goutham Reddy, Senior Consultant Oncologist and Founder & Managing Director of Cancer Shield Pvt Ltd. With a rich background in Medical Oncology, Radiation Oncology, and Palliative Care, Dr. Reddy shares valuable insights into the role of radiation therapy in cancer treatment, addressing common myths, clinical facts, and patient-centered approaches. Hosted by Suhasini, this episode offers clarity and confidence to those facing cancer.Host : SuhasiniGuest : K.C.Goutham ReddyYou Can Reach K.C.Goutham Reddy @linkedin.com/in/k-c-goutham-reddy-534b183b#TALRadioEnglish #CancerCare #RadiationTherapy #Oncology #HealthcareLeadership #PatientSupport #TALHospitals #MedicalOncology #PalliativeCare #CancerAwareness #HolisticHealing #ClinicalInsight #TouchALife #TALRadio

On this week's show, your host, Justin Mog, scrubs your aural environment of all toxins with two colleagues from the University of Louisville's Center for Integrative Environmental Health Science (CIEHS): Cat Aiton, MSW, is the Community Resource Coordinator for the Community Engagement Core of CIEHS, and Sarah Jump is the Communications & Marketing Specialist. Learn more about the Center at https://louisville.edu/ciehs On the show, we discuss what environmental health is and how we all play a role in either advancing it or detracting from it. We share some practical tips for keeping yourself, your family, and your entire community healthy in the face of a world of dangerous toxins and pollutants. We talk about how the Center is working to reach young people with empowering messages and walking the talk with more sustainable give-aways. You'll also learn about an upcoming Conference for Advancing Participatory Sciences and the importance of Report Back strategies for sharing findings with communities in a language that is meaningful to them. We'll also tell you all about the upcoming Environmental Health Youth Academy that the Center is organizing this summer (https://events.louisville.edu/event/2025-ciehs-cec-environmental-health-summer-youth-academy). The deadline to apply for this free summer series in June 16th and it is open to all high school sophomores, juniors, and seniors. CIEHS will host a two-week Youth Academy focused on environmental health in Louisville, July 14-24! At the end of the academy, participants will receive a certificate and a letter of completion (plus some free sustainable swag), making this a valuable addition to college or job applications. We have limited spots available—only 20 students will be accepted for this exclusive summer program, where you will learn directly from environmental health experts. Applications must be submitted by June 16th! Learn more and apply at https://louisville.edu/ciehs. The schedule for the Youth Academy is as follows: July 14 (In Person with lunch): Introduction to Environmental Health Banrida Wahlang, PhD, UofL Gastroenterology, Hepatology and Nutrition Lu Cai, MD, PhD, UofL Pediatrics, Radiation Oncology, and Pharmacology & Toxicology July 15 (Virtual): Air Quality and Health Petra Haberzettl, PhD, UofL Medicine, Diabetes & Obesity Center July 16 (Virtual): Water & Health Mayukh Banerjee, PhD, UofL Pharmacology & Toxicology July 17 (In Person with lunch): Community-Led Science Ted Smith, PhD, UofL Medicine and Pharmacology/Toxicology Rachel Neal, PhD, UofL Biology Luz Huntington-Moskos, PhD, RN, CPN, FAAN, UofL School of Nursing July 21 (Virtual): Energy & Health Sumedha Rao, Mayor's Office of Sustainability July 22 (Virtual): Mapping the Issues Charlie Zhang, PhD, UofL Geographic & Environmental Sciences, DJ Biddle, Director and Senior Lecturer, UofL Center for Geographic Information System Laura Krauser, UofL's Geographic Information Sciences Research Coordinator July 23 (Virtual): Communicating Sustainability Brent Fryrear, UofL Sustainability Council July 24 (In Person with lunch): Policy Advocacy and Storytelling Dr. Tony Arnold, UofL Law, Urban and Public Affairs, Resilience Justice Project Angela Story, PhD, UofL Anthropology and Director of Anne Braden Institute As always, our feature is followed by your community action calendar for the week, so get your calendars out and get ready to take action for sustainability NOW! Sustainability Now! is hosted by Dr. Justin Mog and airs on Forward Radio, 106.5fm, WFMP-LP Louisville, every Monday at 6pm and repeats Tuesdays at 12am and 10am. Find us at http://forwardradio.org The music in this podcast is courtesy of the local band Appalatin and is used by permission. Explore their delightful music at http://appalatin.com

Are you or a loved one facing a diagnosis of bladder cancer, melanoma, or skin cancer? Tune in to this essential episode of Navigating Cancer TOGETHER for expert guidance and compassionate insights. Join host Talaya Dendy as she welcomes back Dr. Thomas Eanelli, a highly respected radiation oncologist based in New York. We also feature Angel Santana, co-host of The CROC Podcast, sharing powerful motivational perspectives. In observance of May Cancer Awareness, this special episode dives into critical aspects of three specific cancers: bladder, melanoma, and skin cancer. Dr. Eanelli provides invaluable medical expertise on the latest cancer treatments, diagnosis, and management of these diseases. Angel Santana offers heartfelt inspiration and emphasizes the power of support and positivity throughout the cancer journey. This episode is packed with vital information and moving stories to offer hope and guidance for anyone navigating cancer.

Dr. Mamta Singhvi defies every stereotype you thought you knew. A Trump supporter with degrees from UCLA and Harvard. Board Certified in Radiation Oncology & Integrative Medicine a scientist who speaks openly about miracles. The daughter of Indian immigrants who advocates for stronger borders. She graduated summa cum laude from UCLA, became the youngest graduate in her medical school class, earned a Masters from Harvard School of Public Health, and has practiced in rural America while jetting to over 40 countries. She's visited India more than 50 times- where she received her Yoga teacher training and provided free medical care from El Salvador to Ethiopia. During COVID, while most physicians fell in line, she took a public stand against vaccine mandates. She has a background modeling & pageantry, was selected to serve as ambassador for global clothing brand Bebe, an experience she parlayed into a national cancer awareness campaign. We talk about the rise in cancer, true healing, spirituality and achieving freedom from systems designed to keep us sick and dependent. Chapters00:00 Introduction to Dr. Mamta Singhvi02:50 Embracing Multidimensionality06:43 The Struggle for Authenticity10:11 Facing Dark Fears18:39 Integrative Oncology: A New Perspective30:00 The Role of Faith in Healing39:48 The Intersection of Science and Spirituality41:47 The Power of the Placebo Effect43:50 Spirituality and Health46:15 The Limitations of Western Medicine48:07 The Connection Between Spirituality and Healing51:05 Medical Freedom and the Healing Industry54:07 Embracing Mortality and Living Fully57:15 Ayurveda and Ancient Healing Practices01:01:04 The Role of Personalization in Medicine01:11:44 Rebuilding Trust in the Medical CommunityDr. Singhvi X AccountRADICALLY GENUINE PODCASTDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

Check out this week's QuadCast as we highlight SRS vs. fSRS for hearing preservation in vestibular schwannomas, preoperative immunotherapy in HNSCC, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Check out this week's QuadCast as we highlight the predictive abilities of AI for ADT duration in prostate cancer, how consolidative chemoRT benefits patients with unresectable gallbladder cancer, the benefits of immunotherapy in clear cell GYN cancer, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Editor in Chief Sue Yom hosts four of our artists – Jen Bellon, our journal's Art Editor, who was previously at Dana Farber Cancer Institute/Brigham & Women's Hospital, and now works as an independent art consultant; Annie Lavigne, Assistant Professor of Radiation Oncology at Johns Hopkins University; Josh No, Attending Physician at Kaiser Permanente; and Tony Orlina, Lead Dosimetrist at Dana Farber Cancer Center. They discuss the role of art in their lives, stories of their Red Journal cover artworks, and what they see as the role of art in medicine.

Check out this week's QuadCast as we highlight PROSTOX's ability to predict late GU toxicity, why long course chemoradiation may be better than short course RT in rectal cancer, how to identify aggressive chromosomal alterations in meningiomas, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Editor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.

Check out the this week's QuadCast as we highlight omission of surgery in breast cancer patients, best management of small cell lung cancer, adaptive radiation for cervical cancer, the best approach for prostate brachytherapy boost, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

“There have been many changes since the '70s that have shaped the nurse's role in administering chemo, and in supporting patients. The major change early on was the transition from that of nurses mixing chemo to that of pharmacists. Regulatory agencies like NIOSH and OSHA defined chemotherapy as hazardous drugs, and professional organizations became involved, leading to the publication of the joint ASCO and ONS Standards of Safe Handling,” ONS member Scarlott Mueller, MPH, RN, FAAN, secretary of the American Cancer Society Cancer Action Network Board and member of the Oncology Nursing Foundation Capital Campaign Cabinet, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, ONS member and chair of the ONS 50th Anniversary Committee during a conversation about the evolution of chemotherapy treatment. Along with Mueller, Burbage spoke with John Hillson, DNP, NP, Mary Anderson, BSN, RN, OCN®, and Kathleen Shannon-Dorcy, PhD, RN, FAAN, about the changes in radiation, oral chemotherapy, and cellular therapy treatments they have witnessed during their careers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: 50th anniversary series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 59: Blood and Marrow Transplant Nursing Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice article:Safe Handling—We've Come a Long Way, Baby! ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (second edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS Hematopoietic Stem Cell Transplantation™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Safe Handling Basics Oral Anticancer Medication Toolkit Oral Anticancer Medication Care Compass Patient education guides created as a collaboration between ONS, HOPA, NCODA, and the Association of Community Cancer Centers: IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Hillson: “I remember as a new grad, from back in '98, walking up to the oncology floor. We had patients with pink labels on the chart and that was the radiation oncology service. I hadn't heard of such a thing before. … I'd gone through nursing school and hospital orientation and unit orientation without ever hearing of these therapies. At the time, both the management and the union had no interest in specialist nurses, and the really weren't any books that were targeting the role. And it was very isolating and frightening. I was very glad to find ONS when I moved to the U.S. Right now, the Oncology Nursing Society Manual for Radiation Oncology, Nursing Practice, and Education, it's in its fifth edition and a sixth is underway. There's nothing else like it. Most books are very much geared towards other professions.” TS 5:34 Mueller: “We mixed our chemo in a very small medication room on the unit, under a horizontal laminar flow hood, which we later discovered should have been a vertical laminar flow hood. Initially, we did not use any personal protective equipment. I remember mixing drugs like bleomycin and getting a little spray that from the vial onto my face. And to this day, I still have a few facial blemishes from that.” TS 14:28 Anderson: “As the increasing number of these actionable mutations continue to grow, so will the number of oral anticancer medications that patients are going to be taking. And we are already seeing that there's multiple combination regimens and complex schedules that the patients have to take. So this role the oral oncolytic nurse and the nursing role, like you said, it cannot be owned by one individual or discipline. So it's not a pharmacist; the pharmacies aren't owning this. The nurses are not owning this. It takes a village.” TS 32:12 Shannon-Dorcy: Then as immunotherapy comes into the picture, we start to learn about [cytokine release syndrome]. All of a sudden, we had no concept that this was a deadly consequence. ONS was on the front lines, convening people across the country together so we could speak to the investigative work with science and find ways that we could intervene, how we can look for signs of it early on with handwriting testing.” TS 39:58

Miriam "Mimi" Knoll, M.D., DABR, is the co-founder and CEO of JOWMA and a radiation oncologist at Northwell Health in New York.Dr. Knoll earned her medical degree from New York University School of Medicine and completed her radiation oncology training at Mount Sinai Medical Center in New York.She serves as a section editor for Advances in Radiation Oncology, the peer-reviewed journal of the American Society of Radiation Oncology (ASTRO), and is an active volunteer with ASCO, ASTRO, NRG, and the RTOG Foundation.An international speaker and researcher, Dr. Knoll focuses on the medical workforce, women in medicine, and social media in medicine. She is a Forbes Healthcare contributor and writes for the American Society of Clinical Oncology (ASCO) Connection and various other media outlets.You can follow her on Twitter @MKnoll_MD and on Instagram @Dr.Mimi.K.Sponsor the JOWMA Podcast! Email digitalcontent@jowma.orgBecome a JOWMA Member! www.jowma.org Follow us on Instagram! www.instagram.com/JOWMA_org Follow us on Twitter! www.twitter.com/JOWMA_med Follow us on Facebook! https://www.facebook.com/JOWMAorgStay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

In this episode of GynoCurious, Dr. Amy Novatt welcomes Dr. Beth Tapen, a radiation oncologist based in Northern California, to discuss the intricacies of radiation oncology. They delve into the history and practice of using radiation to treat various cancers, explaining how this powerful yet paradoxical tool has evolved since its inception in the late 19th century. Dr. Tapen shares her journey into the medical field, highlighting experiences from her training and the challenges she faced, including a significant crossroad in her career path and a difficult experience with misogyny in a residency program. The conversation explores the complexities and technological advances in radiation therapy, particularly as it applies to female pelvic and breast cancers. Dr. Tapen details the multi-disciplinary approach involved in planning radiation treatments, including the importance of understanding cancer biology, human physiology, and technological aspects of treatment. She describes the patient experience, from initial consultation through to the administration of treatment, emphasizing the meticulous care that goes into mitigating side effects and customizing the approach based on individual patient needs. Towards the end of the episode, the discussion shifts to the emotional and psychological aspects of oncology care. Dr. Novatt and Dr. Tapen stress the importance of informed consent, the patient's role in their own treatment decisions, and the critical impact of clinical trials on improving cancer care. Questions of comments? Call 845-307-7446 or email comments@radiofreerhinecliff.org Produced by Jennifer Hammoud and Matty Rosenberg @ Radio Free Rhiniecliff

Check out this week's QuadCast where we highlight the link between dental hygiene and oral mucositis risk, the optimal timing of post-treatment PSMA PET scans, the impressive impact of immunotherapy in MSI-high colorectal cancer, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

This week, we welcome Dr. Amar Kishan to our show to discuss the role of radiation oncology in the management of patients with testicular cancer. As our listeners know by now, the management of patients with testicular cancer spans multiple specialities. We always appreciate hearing from our colleagues about their perspective.Episode contents:- What are important studies to send to radiation oncology prior to their appointment? - How radiation is planned for seminoma patients and a discussion of the treatment course- Implications on spermatogenesis, organ function, and infertility - Role of proton therapy?- Emerging therapies****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast